Second Autologous Transplants for Multiple Myeloma (MM) Relapse After a Prior Autologous Transplant (AHCT) – a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR)
Abstract Abstract 504 Background: There is limited data on the outcomes of AHCT for MM as a salvage approach following relapse after an initial (upfront) AHCT. We analyzed the outcomes of second salvage AHCT for relapsed MM. Methods: From the CIBMTR database we identified 187 patients (63% male) who had second AHCT (AHCT2) as salvage for MM relapsing after a prior AHCT (AHCT1). Planned tandem AHCT and AHCT2 within 6 months after AHCT1 were excluded. Cumulative incidence of relapse, non-relapse mortality (NRM) and the probabilities of progression-free (PFS) and overall survival (OS) were analyzed and multivariate analysis performed using proportional hazards models. Results: Median age at transplant was 57 (range 28–72) and 59 years (range 28–74) respectively at AHCT1 and AHCT2 respectively. Median follow up after AHCT2 was 47 months (range: 3–97). The proportion of IgG, IgA and free light chain subtypes was 48, 20 and 18% respectively. Durie Salmon stage at diagnosis was stage I (6%), II (21%), III (59%) respectively. Seven and 13% had serum creatinine > 1.5 mg/dl at AHCT1 and AHCT2 respectively. Conditioning regimen was single agent melphalan was in 78% and 84% for AHCT1 and AHCT2 respectively. At the time of AHCT2, majority (60%) were chemotherapy resistant compared with 80% patients with sensitive disease prior to AHCT1. Median time from AHCT1 to relapse was 18 months, with 32% relapsing within the first year, 29% in the second year, 19% in the third year and 19% beyond the third year after AHCT1. There was heterogeneity in the time to AHCT2 after relapse although 67% had AHCT2 within a year after relapse (median 7 months). Median between AHCT1 and AHCT2 was 32 months with the majority (69%) beyond 24 months. After AHCT2, day 28 engraftment rates of neutrophils and platelets were 96% (95% CI: 93–98) and 88% (95% CI: 83–92). Complete remission (CR) rates after AHCT1 were 43% whereas it was only 25% following AHCT2. After AHCT2, cumulative incidence of relapse at 1, 3 and 5 years was 51, 82, and 91% respectively. After AHCT2, one year NRM was 2%. PFS was 47%, 13% and 5% and OS was 83%, 46% and 29% at 1, 3 and 5 years respectively. In multivariate analysis, those relapsing within 36 months of AHCT1 had a higher risk of relapse (HR 1.58, p = 0.036) and higher risk of treatment failure and inferior PFS (HR1.52, p= 0.04). Mortality was higher for those relapsing early after AHCT1 (<36 months, HR 1.91, p = 0.02). OS was superior and mortality lower for AHCT2 performed after 2004-08 (HR 0.61, p=0.02). Conclusion: AHCT2 can be safely performed in relapsed MM with the best outcomes observed in later relapses (>36 months from AHCT1). OS has improved since 2004, but NRM, relapse and PFS after AHCT2 were not impacted by year of AHCT2. Thus the improved OS likely reflects greater availability of novel agents for post AHCT progression. Disclosures: No relevant conflicts of interest to declare.
Gene Expression Profiling of Pulmonary Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Identifies New Diagnostic Markers, Biological Heterogeneity and Therapeutic Targets.
Abstract To further understand the molecular biology of mucosa-associated lymphoid tissue (MALT) lymphoma, we conducted a comprehensive gene expression study on the Affymetrix platform using total RNA extracted from biopsy specimen of 35 well-characterized pulmonary MALT lymphoma samples and compared them to gene expression profiles of a range of B and T cell lymphoma, such as Burkitt’s lymphoma, diffuse large B-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, multiple myeloma, and peripheral T-cell lymphoma, and normal cellular counterparts, such as different B-cell and T-cell populations, normal plasma cells and lung tussue. Analytical strategies were adopted to negate tissue specific effect such that our results can be generalized to MALT lymphoma from other anatomical sites. We further analyzed the data using functional tools such as gene-set enrichment analysis and gene ontology. Network/pathway analysis was performed using Metacore. Unsupervised clustering of whole dataset (including other lymphoid malignancies and normal cellular counterpart) using genes with variable expression, showed that compared to other B-cell lymphoid malignancies, MALT lymphoma have a prominent T-cell signature. Using established gene expression of different B-cell compartment, we confirmed that MALT has a marginal zone B-cell and memory B-cell cell-of-origin signature. Using ANOVA with post-hoc pair-wise comparison, we identified 4 novel transcripts over-expressed in MALT but not other B-cell tumors, and validated one of these using immunohistochemistry. MALT lymphoma with t(11;18) or t(14;18) over-expressed genes enriched for pathways other than the NFKB pathway such as JAK-STAT and SRC signaling pathways, which may represent novel therapeutic targets. We identified a number of genes with ‘outlier’ expression including RARA and RGS13. However, translocation involving RARA and the immunoglobulin heavy chain locus was not detected by FISH, suggesting other mechanisms of deregulating gene expression were involved. Using unsupervised clustering of only the MALT samples, we found that the molecular heterogeneity within MALT is composed of a group characterized by MALT1 translocations and another group with plasmacytic differentiation. Interestingly, further refinement of this grouping can be achieved by clustering the samples based on ‘outlier’ gene expression. Samples with MALT1 translocations have high expression of RARA, samples with plasmacytic differentiation have high FKBP11 expression and samples with high RGS13 expression tend to have trisomy 3 and reactive follicles. Our study therefore identified novel molecular markers, deregulated pathways and genetic defects in MALT. Furthermore, subgroups with distinct pathological features and anchored by unique pattern of ‘outlier’ gene expression were identified.
Pruritus in Primary Myelofibrosis: Clinical and Laboratory Correlates
Abstract Abstract 5154 Background Recent clinical trials with JAK or mTOR inhibitors in primary myelofibrosis (PMF) have identified pruritus as one of the most treatment-responsive disease traits. However, little is known about the prevalence of pruritus in PMF or its clinical and laboratory correlates. Methods The study population was selected among a consecutive series of patients with PMF seen at the Mayo Clinic and in whom bone marrow histologic and cytogenetic information was available for re-review. JAK2, MPL and IDH mutation status and plasma cytokine levels (IL-1b, IL-1RA, IL-2R, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, TNF-α, G-CSF, IFN-α, IFN-γ, MIP-1a, MIP-1b, HGF, IP-10, MIG, MCP-1 and VEGF) were recorded where available. Overall and leukemia-free survival analyses were performed from time of referral to the Mayo Clinic. Results I: Prevalence of pruritus and other baseline information Among 566 consecutive patients with PMF (median age 62 years; 368 males), the presence (n=90) or absence (n=146) of pruritus was documented in 236 patients. The prevalence of pruritus was 38% when considering only those patients in whom pruritus history was documented (n=236), and 16% when all study patients (n=566) were considered regardless of whether or not the absence of pruritus was documented in their history. Among the 90 patients with pruritus, it was severe enough to warrant specific therapy in 51 (57%) patients, was aquagenic in 29 (32%), and onset antedated PMF diagnosis in 15 (17%). All 236 patients had information on karyotype: 136 normal, 76 favorable and 24 unfavorable karyotype. Information on JAK2, MPL, and IDH mutations was available in 197 (125 positive), 147 (9 positive), and 131 (2 positive) patients, respectively. In addition, plasma levels of the aforementioned cytokines were available in 63 patients. Results II: Clinical correlates Parameters at diagnosis that were significantly associated with presence of pruritus included leukocytosis (p=0.03), absence of leukopenia (p=0.002), and absence of MPLW515 mutation (p=0.02). Borderline significance was noted for JAK2V617F positive status (p=0.08). The incidence of pruritus was 0% (0/9) vs. 41% (56/138) in MPL-mutated vs MPL-unmutated cases and 42% (52/125) vs. 29% (21/72) JAK2 mutated vs unmutated cases, respectively. No significant correlations were noted for age, DIPSS-plus scores, transfusion need, karyotype, or plasma cytokine levels. The association with leukocytosis/leukopenia was subsequently shown to be significant only in JAK2V617F-negative cases. To date, 124 deaths and 19 leukemic transformations have been documented. In JAK2-mutated cases (n=125), pruritus did not affect overall or leukemia-free survival. In JAK2-unmutated cases (n=72), a significant correlation between presence of pruritus and inferior leukemia-free survival was noted (p=0.04), and was independent of leukocytosis, thrombocytopenia or abnormal karyotype. Conclusions Pruritus accompanies PMF in a substantial proportion of patients and is more or less likely to occur in the presence of JAK2 or MPL mutations, respectively. In JAK2V617F-negative cases, PMF-associated pruritus clustered with leukocytosis and was independently associated with inferior leukemia-free survival. Disclosures: No relevant conflicts of interest to declare.
Primary Central Nervous System (PCNS) Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 65 Cases in the Modern Era
Abstract Abstract 879 Background: Several solid organ transplant (SOT) PTLD series have reported that PCNS disease is a poor prognostic factor (e.g., Leblond et al, JCO 2001; Maeker et al, JCO 2007; Knight et al JCO 2009; Evens et al, JCO 2010). However, these reports contained small PCNS PTLD numbers and most series studied patients (pts) in the pre-rituximab era. Methods: We performed an International retrospective analysis of PCNS SOT-related PTLD diagnosed from 1998 through 2010. Cases with secondary CNS localization were excluded. Detailed pt and disease characteristics, including frontline therapy, were evaluated. Fisher's exact test was used to compare PCNS PTLD vs non-PCNS PTLD cases. Further, univariate associations with survival were determined, while a multivariate Cox regression proportional hazards model was performed. Results: 71 PCNS PTLD cases were identified, of which 65 had complete data. There were 35 men and 30 women; the median age was 53 years (range, 20–77 years). The most common type of SOT was kidney in 72%, followed by lung 18% and 5% each pancreas and heart. The median time from SOT to PCNS PTLD was 46 months (range, 2 to 504 months). Further, only 18% occurred within 12 months of SOT, and 32% of PTLD diagnoses occurred > 10 years after SOT. 85% of pts had received prior mycophenolate, while 30% received tacrolimus prior to PCNS PTLD. According to WHO histology, 83% of PCNS PTLD cases were monomorphic subtype (all B-cell), while tumor was EBV+ in 93% despite EBV being detectable in the peripheral blood (by PCR) in only 38% of these cases. In addition, 49% of pts had poor performance status (i.e., 2–4), 48% had elevated LDH, and 48% were hypoalbuminemic at diagnosis. Interestingly, several of these characteristics were notably different when compared with a non-PCNS PTLD cohort (Table 1A). All pts here presented with CNS-related symptoms and 98% had abnormal findings on MRI showing a parenchymal brain lesion(s); 50% of pts had >1 CNS lesion and 40% had involvement of deep regions of the brain. Further, 12% had concomitant CSF involvement, while no pts had ocular involvement. In terms of therapy, 89% of pts had reduction in immunosuppression (RI). Additional frontline therapy consisted of high dose methotrexate (HD-MTX)-based therapy in 43% (46% of whom also received concurrent rituximab), whole-brain radiation in 20% (61% with rituxmab), high-dose cytarabine (HDAC)-based in 15% (30% with rituximab), while 11% received rituximab alone and 11% had no other therapy (i.e., RI alone). Altogether, 48% of pts received rituximab as part of initial therapy. The overall response rate (ORR) was 55% with 30% complete remission (CR) rate. With a median follow-up of 39 months (1–135), the 3-year progression-free survival (PFS) and overall survival (OS) for all pts were 31% and 32%, respectively (Figure 1). Pts who received rituximab vs not as a component of first line therapy had superior PFS (40% vs 22%, respectively, p=0.02) and borderline improved OS (43% vs 22%, respectively, p=0.06), while pts who did not receive rituximab nor HD-MTX-based therapy as frontline therapy did particularly poor (PFS and OS both 10%). Several pre-treatment and treatment-related factors predicted survival on univariate analysis (Table 1B). When analyzing only pre-treatment related factors in the Cox multivariate regression model, only increasing age remained significant (PFS: HR 1.04 [95%CI 1.00–1.07], p=0.031; and OS: HR 1.04 [95%CI 1.01–1.08], p=0.020). With treatment-related factors included in the model, response to frontline therapy (CR or partial remission) was the dominant predictive factor of survival on multivariate analysis (PFS: HR 0.136 [95%CI 0.047–0.390], p=0.0002; and OS: HR 0.130 [95%CI 0.045–0.381], p=0.0002). Conclusion: These data represent the largest report of PCNS PTLD to date. PCNS PTLD appears to represent a distinct biologic and clinical entity within the PTLD spectrum that retains EBV positivity, occurs late, and presents with additional high-risk features. Furthermore, outcome of PCNS PTLD remains overall modest. However, these data suggest that rituximab and HD-MTX appear to favorably impact survival. Continued study of this subset of pts is critically needed. Disclosures: No relevant conflicts of interest to declare.
Transferrin Saturation (TS) Is a Surrogate Marker for Iron Deficiency Anemia (IDA),
Abstract Abstract 3175 Background: Iron deficiency anemia (IDA) is an important entity in clinical practice. Distinguishing between IDA and other kinds of anemia is challenging in many situations. Various laboratory indices have been studied in relation to IDA including red cell distribution width (RDW), mean cell volume (MCV), transferrin saturation (TS), total iron binding capacity (TIBC), serum ferritin and erythrocyte protoporphyrin (EPP). Methods: We chose 8015 subjects in the National Health and Nutrition Examination Survey (NHANES) database between 2003–2008 who had the required hematologic values. After applying the Centers for Disease Control (CDC) definition for anemia, the number of anemic subjects became 627 (8%). After applying the IDA model as suggested by Cogswell et al using the log ratio of transferrin receptor to ferritin, 46.1% of the anemic subjects had IDA. Then we developed receiver operator (ROC) curves for MCV, RDW, erythrocyte protoporphyrin, TIBC, and percent transferrin saturation for those anemic subjects with and without iron deficiency. From these variables, the area under the curves (AUC), sensitivity, specificity, positive likelihood ratios (LR+), and negative likelihood ratios (LR-) along with their confidence intervals (CI) were calculated. Furthermore we investigated the performance of each available measure by sub-setting the subject group into variables. Data analysis was done using SAS (version 9.2), R version 9.2 with the ROCR library, and MedCalc (version 11.2; MedCalc Software, Mariakerke, Belgium). ROCR and MedCalc have slightly different but individually valuable approaches to ROC curve analysis. Confidence intervals for sensitivity, specificity, and the likelihood ratios were calculated. Results: For the 627 anemic subjects, median age was 26.1 year with 95% being females. Fifty four percent were African American (AA). The MCV showed an AUC of 0.666, sensitivity of 73.7, specificity of 58.8, LR(+) of 1.79, LR(−) of 0.45 with a criterion of <81.6. RDW showed an AUC of 0.803, sensitivity of 77.2, specificity of 69.2, LR(+) of 2.51, LR(−) of 0.33 with a criterion >13.9. For 535 subjects with anemia the EPP showed an AUC of 0.831, sensitivity of 66.4, specificity of 84.9, LR(+) of 4.41, LR(−) of 0.40 with a criterion >93. For 542 subjects with anemia the TIBC showed an AUC of 0.756, sensitivity of 80.3, specificity of 61.5, LR(+) of 2.09, LR(−) of 0.32 with a criterion >406. Finally for the same 542 subjects the TS showed an AUC of 0.869, sensitivity of 80.3, specificity of 78.8, LR(+) of 3.79, LR(−) of 0.25 with a criterion <10.4 [Figure 1]. Comparing the LR(+) and LR(−) between the indices in the setting of inflammation showed that the EPP is the least affected but all indicators are, to some extent, affected by inflammation. Comparing the LR(+) and LR(−) between the indices in the setting of pregnancy showed that TS is the strongest performer. Finally; comparing the LR(+) and LR(−) between the indices in the AA versus non-AA showed that AA ethnicity has a small impact on the LR(−) but reduces the clinical utility of the LR(+) somewhat. Conclusion: Alternative hematologic indices have diagnostic value in the diagnosis of IDA. Transferrin saturation (TS) is the most efficient alternative to ferritin in most circumstances. Erythrocyte proto-porphyrin (EPP) should be considered as an alternative tool in inflammatory conditions. Disclosures: No relevant conflicts of interest to declare.
Selective Inhibition of JAK2 Driven Erythroid Differentiation of Polycythemia Vera Progenitors
Abstract Myeloproliferative disorders (MPDs), diagnosed in 15,000 individuals annually, are characterized by overproduction of lineage-committed blood cells, thrombotic events, occasionally marrow fibrosis or progression to acute myelogenous leukemia and frequently a point mutation (V617F) in the JAK2 kinase. Mutant JAK2 expression results in erythrocyte overproduction in almost all cases of polycythemia Vera (PV). We investigated the molecular mechanisms driving erythroid skewed differentiation and the capacity of a selective JAK2 inhibitor (TG101348) to normalize PV progenitor differentiation. Both JAK2 V617F+ transduced cord blood and PV progenitor erythroid colony formation was potently inhibited by TG101348 (300 nM). Bioluminescent immunocompromised mouse transplantation studies revealed that TG101348 (150 mg/kg) treatment significantly reduced human erythroid engraftment by both PV and JAK2 V617F+ cord blood progenitors. Moreover, the imbalance between GATA-1 and PU.1 transcripts typical of JAK2 V617F+ progenitors normalized after treatment with TG101348. In addition, TG101348 inhibited both JAK2-mediated STAT5 phosphorylation and AKT-regulated GATA-1 phosphorylation in an erythropoietin responsive cell line suggesting a dual mechanism for the erythroid inhibitory effects of TG101348. Because of selective inhibition of JAK2 V617F+ progenitors both in vitro and in vivo, TG101348 may be an effective molecularly targeted inhibitor of JAK2 V617F+ driven MPDs in clinical trials.
Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG
Abstract Abstract 880 Pulmonary marginal zone lymphoma is a distinct subgroup of B-cell non-Hodgkin's lymphomas originating from the bronchial-associated lymphoid tissue (BALT) and characterized by an indolent clinical course. Here we present the data of the IELSG-28 study of the International Extranodal Lymphoma Study Group (IELSG) on primary pulmonary lymphoma patients. Clinical records and histological material of 186 patients diagnosed with pulmonary marginal zone lymphoma from December 1986 to June 2009 were collected. The pathology was reviewed centrally and the diagnosis was confirmed in 180 (96%) patients. The median age at diagnosis was 62 (30 – 88). The majority of the patients (149/180) had localized disease at diagnosis with a good performance status (0–1) and low prognostic index (IPI 0–2). Eighty-one patients (45%) received local treatment, including surgery (74%) or radiotherapy (4%). Ninety-nine patients with advanced stage disease or incomplete surgical resection received an additional systemic treatment. Most of these patients (66; 66%) received an alkylating containing regimen, 22 (22%) patients were treated with an anthracycline containing regimen and 29 (29%) received the anti-CD20 monoclonal antibody in combination with chemotherapy. With a median follow up of 67 (range 1–256) months, 47/180 patients (26%) experienced disease progression. (median time to progression 30 months, range 0–109). Progression free survival analysis showed a trend in favour of patients treated with immuno-chemotherapy versus those receiving chemotherapy alone (HR 0.53–95%CI: 0.21, 1.33), while no difference in terms of OS and PFS was observed between patients receiving systemic anthracycline or alkylating containing regimens. In twenty five cases a specific PCR-assay was carried out for detecting the presence of Achromobacter (Alcaligenes) xylosoxidans. The presence of Achromobacter was detected in 50% of patients. Our results confirm that local therapy (surgery or radiotherapy) is the treatment of choice for patients with localized disease. Chemotherapy has to be considered in case of relapse, incomplete surgical excision or advanced disease. In this setting, alkylating containing regimens plus rituximab is the most effective option. Further studies are ongoing to confirm the relevance of infection/colonization with Achromobacter (Alcaligenes) xylosoxidans for pathogenesis of BALT lymphoma. Disclosures: No relevant conflicts of interest to declare.
Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma
Abstract Background Pomalidomide (POM) is the newest Immunomodulatory agent (IMiDs) that has shown clinical efficacy in relapsed multiple myeloma (MM) refractory to lenalidomide (LEN) and thalidomide (THAL). Studies of MM cell microenvironment suggest that tumor subclones compete for dominance during changes in drug therapy. It was previously observed that a minor clonal population increased in prominence of MM cells after 1 year of treatment with LEN. We examined whether the patients having THAL or LEN as the most recent prior-line therapy affects response to POM. Methods We studied 208 patients enrolled in a phase II trial of POM / dexamethasone between November 2007 and March 2012 at Mayo Clinic, Rochester. We reviewed the immediate prior-line therapy before enrollment in our trial. Comparison of treatment duration of POM and response rates were conducted between patients who had either THAL or LEN as latest prior-line therapy, and patients who were treated with non-IMiDs immediate before enrollment in POM trial. Treatment duration of POM was estimated using Kaplan Meier method and the survival curves were compared using log-rank test. We used univariate Cox proportional hazard models to estimate the prognostic impact of different variables. Results The median age of patients was 63 (range from 32 to 88). 68 % were males. 80 patients (38.5%) had THAL or LEN immediate prior to POM. Median prior-line therapies were 3. Patients who received THAL or LEN immediately prior to POM had a lower response rate than those who had non-IMiDs as latest therapy (29% vs 44%, p 0.04) and shorter median duration of POM treatment (5.7 months vs 7.3 months, p 0.02). In 190 (91%) patients who were previously treated with LEN and THAL at any time, median time between the end of LEN or THAL treatment and the initiation of POM was higher for POM responders than non-responders (10 months vs 3 months, p 0.0008). Patients responded to POM had a shorter duration of prior LEN or THAL treatment compared to non-responders (9 months vs 15 months, p 0.001). Conclusion THAL or LEN as an immediate prior-line therapy to POM is associated with a lower response rate and shorter effective treatment duration. Longer interval between prior immunomodulatory compounds and POM, and shorter exposure to previous immunomodulatory compounds are associated with better POM treatment response. Disclosures: Gertz: Celgene: Honoraria. Kumar:Merck: Consultancy, Honoraria; Celgene: Consultancy, Research Funding; Millennium: The Takeda Oncology Company: Research Funding; Novartis: Research Funding; Genzyme: Research Funding. Lacy:Celgene Corporation: Research Funding.
Mass Spectrometry-Based Proteomics Reveals Distinct Immunoglobulin Light Chain Variable Region Usage In Systemic Versus Localized AL Amyloidosis
Abstract Background Immunoglobulin light chain-associated amyloidosis (AL) is caused by deposition of immunoglobulin light chain molecules with unique, clonotypic variable (V) regions. Detection and identification of the V region, however, has been challenging due heterogeneity inherent in V regions. We developed a new method for detecting IGKV and IGLV region fragments in AL deposits using protein mass spectrometry and novel bioinformatics approach. We report distinct IGKV and IGLV usage in localized versus systemic AL. Methods Shotgun protein mass spectrometry on amyloid plaques was performed as previously described (Blood. 2009; 114: 4957-9). Peptide tandem mass spectra (MS/MS) were searched against a composite sequence database containing SwissProt's human complete proteome augmented with 1764 IG V region sequences obtained from ImMunoGeneTics database and a Mayo Clinic internal database. Reversed sequences were appended to the database for estimating identification false discovery rates (FDRs). Peptide identifications were processed with Scaffold software. Confident protein identifications (probability > 0.9) with at least one unique peptide identifications and five MS/MS matches were considered. Detected variable gene family (if any) with most number of peptide and spectral matches is considered to be present in the deposit. The method was first validated in 8 cases of AL amyloidosis with known IGKV and IGLV region sequences and then applied on 1238 systemic and 393 localized AL cases. Differences between groups were measured by generating hypergeometric p-values. Results In all 8 AL cases with known IGKV and IGLV region usage, gene family identified in the AL deposit via proteomics matched the gene family inferred from bone marrow plasma cells by Sanger sequencing of IGLC genes. Armed with this method, we analyzed the amyloid proteomics data from 1238 patients with systemic AL amyloidosis and 393 patients with localized AL amyloidosis. The anatomical site distribution in systemic cohort was 296 GI tract, 364 heart, 225 kidney, 81 liver and 272 fat aspirate; Localized cohort has 78 bladder, 158 lung and 157 skin cases. Figure 1 shows the normalized frequency of the variable gene families detected between the systemic and localized AL amyloidosis. For AL-kappa, KV1 was more prevalent in systemic cases when compared to localized cases (p=7.2E-12) suggesting KV1 clones as a hallmark for systemic AL-kappa amyloidosis. KV3 was more frequently seen in localized AL-kappa cases when compared to systemic AL-kappa cases (p =2.8E-11). For AL-lambda, LV1 and LV2 gene families were more prevalent in localized cases when compared to systemic cases (p= 0.039 and 2.7E-05). LV6 was more prevalent in systemic AL-lambda cases (p=1.4E-07). We also detected a higher incidence of mixed AL/AH type in localized AL (18%) when compared to systemic AL (5%; Odds Ratio=4.2673, p<0.0001). We next turned to the organ specific IGKV and IGLV gene family usage patterns in patients with localized amyloidosis. For 147 localized AL-kappa cases, KV3 was most dominant in lung (64%) and KV1 was dominant in skin (38%). For 246 localized AL-lambda cases, LV2 was most prevalent in lung (34%) and LV3 was most prevalent in skin (36%). For bladder, both LV1 and LV2 had comparable prevalence (42% and 32%). For 361 systemic AL-kappa cases, KV1 consistently ranked at the top of gene families used in GI tract (55%), heart (71%), kidney (59%), liver (75%) and fat aspirate (50%). For 877 systemic AL-lambda cases, LV2 was predominant in GI tract (30%), LV3 in heart (35%) and LV6 in kidney (33%). The prevalence of LV1, LV2 and LV3 in liver is comparable (36%, 22% and 31%). LV6 and LV3 had comparable prevalence (22% and 24%) in AL-lambda fat aspirates. Conclusion The novel proteomics method detects IGLC V family usage in large cohorts of AL patients. It identifies unique profiles in systemic and localized cases, and in different organ sites. This information will be helpful in determining systemic versus localized nature of AL amyloidosis at diagnosis and to assess risk of specific end organ involvement. We found also a strong association between IGKV and IGLV gene usage and organ involvement. Disclosures: No relevant conflicts of interest to declare.
The Histone Methytransferase MMSET Regulates Class-Switch Recombination
Abstract Abstract 691 Malignant plasma cells in multiple myeloma (MM) patients display a variety of recurrent genetic abnormalities. In this regard, tumor cells in approximately 15% of all MM patients will exhibit a translocation involving the immunoglobulin (Ig) heavy chain locus at 14q32 and the short arm of chromosome 4. The breakpoint on chromosome 4 (4p16) frequently results in overexpression of FGFR3 and/or full-length or truncated versions of the multiple myeloma SET domain protein, MMSET. MM patients with t(4;14) translocations are considered to have high-risk disease. MMSET has been shown to have histone methyltransferase activity and we have recently shown that this protein plays a pivotal role in DNA repair and maintenance of genetic stability (1). Thus, dysregulation of MMSET may result in aberrant responses to DNA damage, which may be related to the poor prognosis of MM patients with t(4;14) translocations. The MMSET gene is also known as the Wolf-Hirschhorn syndrome candidate (WHSC1) gene. Expression of the WHSC1 gene is uniformly misregulated due to haploinsufficiency in patients with Wolf-Hirschhorn syndrome (WHS) resulting in characteristic facial features and developmental disorders. Of great interest, WHS patients also display significant antibody deficiencies and IgG and IgA deficiencies are particularly frequent. Currently, the underlying cause of antibody deficiencies in WHS patients remains unknown. However, our recent studies have shown that a robust DNA repair process in germinal center B cells is required for fertile antibody maturation processes (2). This observation, taken together with our recent discover that MMSET regulates the recruitment of 53BP1 to sites of DNA damage through its histone methyltransferase activity during DNA damage repair (1), suggested to us the hypothesis that MMSET may also be critically involved in Ig gene maturation, particularly as it concerns class switch recombination, a process known to result from double strand DNA breaks and subsequent effective DNA repair. By using shRNA knockdown technology in murine lymphoma cell line CH12F3 cells, which can be specifically induced to switch from IgM to IgA expression ex vivo by CD40 ligand stimulation in the presence of IL-4 and TGFb, we clearly demonstrate that downregulation of MMSET expression by shRNA significantly impaired class switch recombination from IgM to IgA. While it plays no detectable roles in cell viability, proliferation, or apoptosis, we found that MMSET is important for histone methylation at H3K36 and H4K20 sites of the Igh loci, which in turn modulate the recruitment of 53BP1 to the Igh loci as well as the transcription of the Igh switch regions, leading to defective class switch recombination. Further DNA sequence analysis of post-switched Sm-Sa junctions from MMSET compromised cells showed a significant increase in microhomology suggesting that homologous recombination (HR) repair is alternatively used as a compensatory mechanism during DNA repair of the switch region when MMSET is absent. Our results suggest that defective CSR caused by MMSET deficiency may underpin the antibody deficiency phenotype in WHS patients. Furthermore, our results showing that MMSET expression dose dictates the usage choice between two competing DNA repair pathways, i.e., error-prone non-homologous end joining (NHEJ) and error-free HR, may also suggest that MMSET overexpression in MM may favor usage of the NHEJ pathway therefore leading to more error-prone DNA repair and possibly additional genetic damage. Disclosures: No relevant conflicts of interest to declare.